Politics Nicholas Florko CBD is all the rage among patients. It’s launching their physicians into uncharted territory
First Opinion Jordan Tishler Cannabis legalization must address medical use, not just recreational use
First Opinion Kevin Doyle Decriminalization could help ease the nation’s drug epidemic, but the devil is in the details
Politics Nicholas Florko Congress asked the FDA to explain its rules on CBD — but its new report offers little clarity
Health Megan Thielking One in five high school seniors vaped marijuana in the last year, fueling concern among health officials
Biotech Nicholas Florko The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism
Pharmalot Ed Silverman Pharmalittle: Trump administration pushes for international drug pricing index; is Roche starting a price war in cancer drugs?
First Opinion Beatriz H. Carlini, Gregory Carter and Nephi Stella Cannabidiol confusion: lofty promises and barriers to research
Politics Nicholas Florko At first-ever public hearing on CBD, advocates and FDA try to blaze trail to regulatory compromise
Politics Nicholas Florko Dude, where’s my regulatory framework? As CBD gains popularity, Washington struggles to keep up
Health Felice J. Freyer — Boston Globe Harvard, MIT share $9 million gift to study marijuana’s health effects
Health Talia Bronshtein INTERACTIVE: Explore how illegal drugs have become cheaper and more potent over time
Politics Stephanie Simon Marijuana and soda taxes win big, but cigarette taxes fail in several state votes
Politics Leah Samuel Hair testing for drug use gains traction — but critics say the science needs to catch up